Oxonica Inc. President to Showcase the First Application of Oxonica's Nanoparticle Based Tags for Point-of-Use Lateral Flow Immunoassays
A subsidiary of Oxonica plc, Oxonica Inc. was established in December 2005 following Oxonica's acquisition of Nanoplex Technologies and the latter's subsequent merger with Oxonica Healthcare. Dr. Michael Natan was founder and president of Nanoplex Technologies and is now president of Oxonica Inc.
“SERS Nanotags: A Powerful New Detection Modality for Diagnostics”
In his address, Dr. Natan will discuss Oxonica's nanotags' particular capabilities for lateral flow immunoassays, the format routinely used for home pregnancy tests, infectious disease diagnosis, biothreat agents and drug abuse detection.
Point-of-care or point-of-use testing is estimated to generate revenues of $6.8 billion globally. Within this segment the current US market for lateral flow immunoassay is estimated at $625 million. Industry leaders believe that a significant market potential exists for a rapid diagnostic format that is capable of precise quantitative measurement of multiple analytes. Rapid, point-of-use testing is seen as an important tool in significantly improving patient care and reducing healthcare costs.
Although routinely employed for their ease of use, current lateral flow devices suffer from an inability to provide robust, quantitative results. Moreover, while physicians are increasingly concerned with panels of biomarkers, lateral flow devices are typically designed to detect only one type of biomarker at a time. Oxonica is developing nanotags for lateral flow devices to enable rapid, quantitative measurement of multiple disease markers. The product being showcased has a three marker panel for respiratory diseases. Oxonica is working towards the next key milestone in this area to increase the number of possible markers and to improve the quantitative measurement of these markers. In parallel, Oxonica is currently looking for a commercial partner to help co-develop this technology over the next three to five years into a product format with regulatory approval.
Dr. Natan will deliver the luncheon keynote, entitled "SERS Nanotags: A Powerful New Detection Modality for Diagnostics," at 1 pm on Thursday, February 23, as part of the conference's Molecular Diagnostics track. For more information, visit Oxonica Inc. in the conference exhibit hall at booth number 403 or online at www.oxonica.com.
About Oxonica Inc.
Oxonica Inc. is a leading developer of commercial nanotechnology-enabled products for global health and personal care markets. Established in 2005 by the merger of Oxonica Healthcare and Nanoplex Technologies, Oxonica Inc., is actively engaged in developing transformational detection technologies that will enable a new generation of standardized ultra-sensitive multiplexed diagnostic tools for applications from drug development through point of care. Oxonica Inc. is headquartered in Mountain View, CA.
About Oxonica plc
Oxonica is one of the leading European nanomaterials groups with products already launched into international markets. It was spun-out from Oxford University in 1999 and currently employs 54 professional staff. Oxonica's mission is to develop innovative commercial solutions for international markets using its expertise in the design and application of nanomaterials. The company has three operating divisions: Oxonica Energy, Oxonica Healthcare and Oxonica Materials.
Commercialised products are:
Envirox(TM) Fuel Borne Catalyst -- a fuel borne nanocatalyst for diesel engines which reduces fuel consumption with savings of 5-10% and reduces particulate emissions by up to 15%. The product has already been adopted by Stagecoach Group in the UK and is distributed by Veridium Technology Inc. to petroleum companies in the Philippines for use in a premium diesel.
Optisol(TM) UV Absorber -- a photostable UV absorber that provides enhanced and longer lasting protection against UVA in sun-care and anti-ageing products. Optisol(TM) also reduces the formation of free radicals produced from exposure to the sun and which are implicated in premature skin ageing. Boots Group plc was the first to incorporate Optisol(TM) in their new Soltan Facial Sun Defense Cream for 2005.
In addition, Oxonica is working to generate a range of future product applications. These include additional fuel saving additives, biomarker detection technology for the clinical and life science diagnostics markets, further UV protection applications, including tailoring the Optisol(TM) product in the cosmetics markets, and new products for plastics and coatings, transparent conducting films and security markers.
Optisol(TM) and Envirox(TM) are trademarks of Oxonica.
For further information, please visit www.oxonica.com.